Search results
Results from the WOW.Com Content Network
Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). [11] It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. [ 11 ]
Daily Assessment of Symptoms – Anxiety; Generalized Anxiety Disorder 7 (GAD-7) [4] [5] Hamilton Anxiety Scale (HAM-A) [6] [7] Hospital Anxiety and Depression Scale; Panic and Agoraphobia Scale (PAS) Panic Disorder Severity Scale (PDSS) PTSD Symptom Scale – Self-Report Version; Screen for child anxiety related disorders
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [8] It is primarily used to treat major depressive disorder and, perhaps more-especially, obsessive–compulsive disorder (OCD), [9] but is also used to treat anxiety disorders [10] such as panic disorder, social anxiety disorder, and post-traumatic stress ...
They are not recommended as the first-line anti-anxiety drugs, but they can be used in combination with SSRIs/SNRIs during the initial treatment stage. [4] Indications include panic disorder, sleep disorders, seizures, acute behavioral disturbance, muscle spasm and premedication and sedation for procedures.
SSRIs are recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of generalized anxiety disorder (GAD) that has failed to respond to conservative measures such as education and self-help activities. GAD is a common disorder of which the central feature is excessive worry about a number of different events.
[2] [3] Alternatively, the Montgomery-Åsberg Depression Rating Scale (MADRS) features ten items to be completed for the purpose of assessing the effects of drug therapy, [2] [4] Another scale is the Raskin Depression Rating Scale rating the severity of the patients' symptoms in three areas: verbal reports, behavior, and secondary symptoms of ...
A 2006 meta-analysis review found wide variation in the findings of prior studies: for people who had failed to respond to an SSRI antidepressant, between 12% and 86% showed a response to a new drug. However, the more antidepressants an individual had previously tried, the less likely they were to benefit from a new antidepressant trial. [ 77 ]
Avoidance coping is measured via a self-reported questionnaire. Initially, the Multidimensional Experiential Avoidance Questionnaire (MEAQ) was used, which is a 62-item questionnaire that assesses experiential avoidance, and thus avoidance coping, by measuring how many avoidant behaviors a person exhibits and how strongly they agree with each statement on a scale of 1–6. [1]